Novel Inhibitors of Sphingosine Kinase

Award Information
Agency:
Department of Health and Human Services
Amount:
$473,108.00
Program:
SBIR
Contract:
1R43CA097833-01A2
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
2003
Phase:
Phase I
Agency Tracking Number:
CA097833
Solicitation Topic Code:
N/A
Small Business Information
APOGEE BIOTECHNOLOGY CORPORATION
PO BOX 916, HERSHEY, PA, 17033
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 KEVIN FRENCH
 (717) 566-8635
 KJFRENCH@APOGEE-BIOTECH.COM
Business Contact
 CHARLES SMITH
Phone: (717) 520-9674
Email: CDSMITH@APOGEEBIOTECH.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The long-term goal of this program is to identify and evaluate novel inhibitors of human sphingosine kinase (SK) as anticancer therapeutic agents. We have focused on SK as a innovative molecular target for cancer therapy because of its critical role in sphingolipid metabolism, which is known to regulate cell proliferation and apoptosis. SK produces sphingosine-1-phosphate which promotes mitogenesis and concurrently depletes ceramide, thereby inhibiting apoptosis. Importantly, recent studies have demonstrated that SK can act as an oncogene. Overexpression of SK in NIH/3T3 cells results in cellular transformation and allows these cells to grow as tumors. Additionally, SK activity has been found to be crucial for Ras-mediated cell proliferation. Furthermore, we demonstrate herein that SK is frequently overexpressed in a variety of human tumors. In spite of this accumulating evidence for a pivotal role of SK in regulating tumor growth, pharmacological inhibition of SK is an untested means of treating cancer. This is due to the current lack of specific SK inhibitors. To overcome this problem, we have initiated a project to identify and evaluate such inhibitors of SK. By screening libraries of synthetic compounds, we have identified novel inhibitors of recombinant human SK. These compounds are more potent than any other known SK inhibitor, and do not compete for the ATP binding site of the enzyme. The SK inhibitors are cytotoxic toward tumor cells, including cell lines with the multidrug resistance phenotype. To provide proof-of-principle evaluations of the potential utility of these compounds, the following Specific Aims will be addressed in Phase I of this project: 1) To evaluate the specificities of SK inhibitors using in vitro and cellular assays; 2) To optimize the SK inhibitory activity of selected chemotypes; and 3) To evaluate the in vivo toxicity, pharmacokinetics and antitumor activity of SK inhibitors.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government